
    
      The polysaccharide vaccine protected 60% of elderly adults who were at risk for pneumococcal
      infection.However, pneumococci are highly diverse with respect to their capsular types , and
      the polysaccharide-protein conjugate vaccines will not protect against strains of the many
      capsular types not included in the vaccine.This experimental vaccine was covered 70% of all
      pneumococcal types, Subjects will receive three doses of PBPV vaccine on day 0,60 and 120
      with different contents of 20μg,50μg,100μg each antigen in 18 to 49 years of age.
    
  